SPC Korea will now be in charge of the domestic supply of two new COPD drugs in Korea.

The company announced it had signed an exclusive agreement for the sales and distribution of two Chronic Obstructive Pulmonary Disease (COPD) treatments with the multinational pharmaceutical company, Covis Pharma GmbH. Under the agreement, SPC Pharm has been exclusively selling and distributing Eklira (Aclidinium bromide)’ and ' Duaklir (aclidinium bromide/formoterol fumarate dihydrate) in Korea from March 1.


Covis Pharma had previously acquired the global rights for Eklira and Duaklir from AstraZeneca. Upon signing the agreement, the exclusive distribution and sales rights for the drugs in Korea w